Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) experienced a decline of 1.24% on February 5, with a trading volume of 48.6647 million yuan [1] - The fund's shares increased by 2 million, bringing the total shares to 2.023 billion, with a total increase of 161 million shares over the last 20 trading days [1] - The latest net asset value is calculated at 1.633 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the National Index for Hong Kong Stock Connect Innovative Drugs (adjusted for valuation exchange rates) [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -19.30%, with a return of -2.93% over the past month [1]

Group 1 - The core point of the article highlights the performance of the Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund Management, which saw a 3.00% increase in value on January 7, with a trading volume of 107 million yuan [1] - The fund's total shares increased by 3 million to reach 1.862 billion, with a notable increase of 179 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 1.631 billion yuan, and its performance benchmark is the Guozheng Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1] Group 2 - Since its establishment on September 12, 2025, the fund has reported a return of -12.45%, while its return over the past month is -1.10% [1] - The fund is managed by Zhang Qisi and Ye Zhenan, indicating a focus on innovative drug investments within the Hong Kong market [1]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) experienced a decline of 1.96% with a trading volume of 47.07 million yuan on December 29 [1] - The fund's shares increased by 5 million, bringing the total shares to 1.815 billion, with an increase of 186 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 1.455 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the National Index for Hong Kong Stock Connect Innovative Drugs, adjusted for valuation exchange rates [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -19.85%, with a one-month return of -10.93% [1]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund experienced a decline of 1.73% on November 17, with a trading volume of 84.4024 million yuan, indicating a potential volatility in the innovative drug sector [1] Group 1: Fund Performance - The fund's latest share count increased by 3 million shares, bringing the total to 1.586 billion shares, with a significant increase of 672 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 1.437 billion yuan [1] - Since its inception on September 12, 2025, the fund has reported a return of -9.41%, while the return over the past month is 1.13% [1] Group 2: Management and Benchmark - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan overseeing its operations [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund experienced a decline of 0.69% on November 11, with a trading volume of 819.30 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The fund's total shares increased by 75 million, bringing the latest total to 1.568 billion shares, with an increase of 818 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 1.355 billion yuan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -13.60%, while the return over the past month is -8.36% [1] Group 2: Management and Benchmark - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1]

Core Viewpoint - The investment safety margin for innovative drugs has increased significantly after a round of adjustments, and the upcoming national medical insurance negotiations in the fourth quarter are expected to catalyze further value in innovative drug investments [2][3]. Group 1: Market Performance - The innovative drug sector experienced a rebound on October 31, with multiple indices rising over 3%, including a 3.71% increase in the Guozheng Hong Kong Stock Connect Innovative Drug Index [3]. - Year-to-date performance shows that several innovative drug indices have increased by over 80%, with some reaching double their values at peak [4]. - Despite a significant adjustment since mid-September, where major indices fell over 10% and some over 20%, the fundamental and policy aspects suggest a potential for continued growth [4][6]. Group 2: Fundamental Drivers - The aging population in China is a fundamental driver for the pharmaceutical sector, with projections indicating that by the end of 2024, there will be 310 million individuals aged 60 and above, accounting for 22% of the total population [5]. - Continuous R&D investment and accelerated expansion into overseas markets are identified as core engines for profit growth among innovative drug companies [5][6]. - As of October 31, 52 out of 80 innovative drug companies reported a year-on-year increase in net profit for the first three quarters, indicating a shift towards sustainable profitability [6]. Group 3: Policy Environment - The "14th Five-Year Plan" emphasizes the acceleration of health initiatives, supporting the development of innovative drugs and medical devices, which lays a solid foundation for the sector's growth over the next five years [6]. - The introduction of the "Commercial Insurance Innovative Drug Directory" in the 2025 national medical insurance negotiations is expected to broaden market opportunities for innovative drugs [6]. Group 4: Investment Opportunities - For ordinary investors, the complexity of investing in innovative drugs suggests that utilizing ETFs may be a more accessible approach [7]. - The Southern Hong Kong Stock Connect Innovative Drug ETF (159297) is highlighted as a noteworthy option, closely tracking the Guozheng Hong Kong Stock Connect Innovative Drug Index, which has been refined to exclude CXO companies, enhancing its focus on pure innovative drug firms [7][8]. - Historical performance data shows that the Guozheng Hong Kong Stock Connect Innovative Drug Index has delivered strong returns over various time frames, making it an attractive investment vehicle [8]. Group 5: Valuation Metrics - As of October 31, the TTM P/E ratio for the Guozheng Hong Kong Stock Connect Innovative Drug Index was 41.09, indicating a relatively low valuation compared to historical levels [9]. - The macroeconomic environment appears stable, with ongoing potential catalysts in the innovative drug sector, including recent breakthroughs at international conferences and favorable domestic policy developments [9].

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) experienced a decline of 4.31% on October 30, with a trading volume of 242 million yuan [1] - The fund's shares increased by 148 million, bringing the total shares to 1.281 billion, with a total increase of 793 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 1.082 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the Guozhen Hong Kong Stock Connect Innovative Drug Index (adjusted for valuation exchange rates) [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -15.57%, with a return of -14.79% over the past month [1]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund experienced a decline of 2.95% on October 22, with a trading volume of 86.9732 million yuan, indicating a challenging market environment for innovative drug investments [1] Group 1: Fund Performance - The fund's total shares increased by 62 million, bringing the latest total to 1.052 billion shares [1] - The latest net asset value of the fund is calculated at 929 million yuan [1] - Since its inception on September 12, 2025, the fund has reported a return of -11.74%, while the return over the past month is -11.10% [1] Group 2: Management and Benchmark - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - The performance benchmark for the fund is the National Index for Hong Kong Stock Connect Innovative Drugs, adjusted for valuation exchange rates [1]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund has shown a recent increase in trading volume and share count, despite a negative return since its inception [1] Group 1: Fund Performance - The Hong Kong Stock Connect Innovative Drug ETF (159297) rose by 2.59% on October 15, with a trading volume of 85.1141 million yuan [1] - The fund's share count increased by 34 million, bringing the total to 784 million shares [1] - The latest net asset value is calculated at 709 million yuan [1] Group 2: Benchmark and Management - The fund's performance benchmark is the Guozhen Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] Group 3: Historical Returns - Since its establishment on September 12, 2025, the fund has recorded a return of -9.56% [1] - Over the past month, the fund's return has been -9.63% [1]

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) experienced a decline of 2.41% on October 13, with a trading volume of 118 million yuan [1] - The fund's shares increased by 71 million, bringing the total shares to 664 million [1] - The latest net asset value of the fund is calculated to be 618 million yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the National Index for Hong Kong Stock Connect Innovative Drugs, adjusted for valuation exchange rates [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -7.04% [1]